TERT and hepatocellular carcinoma: For instance, a recent study from four Chinese centers introduced an assay detecting point mutations in TP53, CTNNB1, AXIN1, and TERT promoter, as well as HBV integration in cfDNA for early detection of HBV-related HCC, which was combined with AFP, des-γ-carboxy prothrombin, and relevant clinical variables, to develop the “HCCscreen” algorithm [141].